Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Façon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al‐Ola Abdallah, Ashraf Badros, Stefan Knop, Edward A. Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso, Niels W.C.J. van de Donk
Topics & Concepts
MedicineDexamethasoneLenalidomidePomalidomideDaratumumabInternal medicineProgressive diseaseMultiple myelomaRefractory (planetary science)CohortInterim analysisGastroenterologyOncologyClinical trialChemotherapyAstrobiologyPhysicsProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways